MVM Life Science Partners

MVM Partners, founded in 1997, is a global venture capital firm focused on high-growth healthcare investments. With offices in Boston and London, MVM invests broadly across sectors including medical technology, pharmaceuticals, diagnostics, digital health, and other healthcare-related fields. Their portfolio includes notable companies such as SkyCell, which developed patented temperature-control technology for safely transporting vaccines and biotech drugs, and Ossio, which created OSSIOfiber Intelligent Bone Regeneration Technology—a novel orthopedic fixation material that integrates into native bone and avoids the need for permanent metal implants. MVM also invested in MDxHealth, a company specializing in molecular diagnostics for urologic cancers, which enhances personalized cancer diagnosis and treatment. MVM's investment strategy emphasizes significant minority stakes in innovative companies, providing both financial support and strategic guidance to help these companies grow and scale. Their approach involves close collaboration with management teams to drive business development and market expansion. MVM's recent investments include companies like eXmoor Pharma, which focuses on cell and gene therapy services, and Nalu Medical, which develops minimally invasive solutions for chronic pain management. These investments reflect MVM's commitment to supporting advancements in medical technology and improving patient outcomes globally.